These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 23384250)

  • 21. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
    Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
    Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues.
    Lin F; Marchetti S; Pluim D; Iusuf D; Mazzanti R; Schellens JH; Beijnen JH; van Tellingen O
    Clin Cancer Res; 2013 Apr; 19(8):2084-95. PubMed ID: 23461902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AST1306, a potent EGFR inhibitor, antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance.
    Zhang H; Wang YJ; Zhang YK; Wang DS; Kathawala RJ; Patel A; Talele TT; Chen ZS; Fu LW
    Cancer Lett; 2014 Aug; 350(1-2):61-8. PubMed ID: 24747122
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cells.
    Yoshikawa M; Ikegami Y; Hayasaka S; Ishii K; Ito A; Sano K; Suzuki T; Togawa T; Yoshida H; Soda H; Oka M; Kohno S; Sawada S; Ishikawa T; Tanabe S
    Int J Cancer; 2004 Jul; 110(6):921-7. PubMed ID: 15170677
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hop-derived prenylflavonoids are substrates and inhibitors of the efflux transporter breast cancer resistance protein (BCRP/ABCG2).
    Tan KW; Cooney J; Jensen D; Li Y; Paxton JW; Birch NP; Scheepens A
    Mol Nutr Food Res; 2014 Nov; 58(11):2099-110. PubMed ID: 25044854
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transcriptional targeting of human liver carboxylesterase (hCE1m6) and simultaneous expression of anti-BCRP shRNA enhances sensitivity of breast cancer cells to CPT-11.
    Mishra MN; Vangara KK; Palakurthi S
    Anticancer Res; 2014 Nov; 34(11):6345-51. PubMed ID: 25368234
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular changes to HeLa cells on continuous exposure to SN-38, an active metabolite of irinotecan hydrochloride.
    Takara K; Kitada N; Yoshikawa E; Yamamoto K; Horibe S; Sakaeda T; Nishiguchi K; Ohnishi N; Yokoyama T
    Cancer Lett; 2009 Jun; 278(1):88-96. PubMed ID: 19201079
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Carboxylesterase-mediated sensitization of human tumor cells to CPT-11 cannot override ABCG2-mediated drug resistance.
    Wierdl M; Wall A; Morton CL; Sampath J; Danks MK; Schuetz JD; Potter PM
    Mol Pharmacol; 2003 Aug; 64(2):279-88. PubMed ID: 12869632
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux.
    Erlichman C; Boerner SA; Hallgren CG; Spieker R; Wang XY; James CD; Scheffer GL; Maliepaard M; Ross DD; Bible KC; Kaufmann SH
    Cancer Res; 2001 Jan; 61(2):739-48. PubMed ID: 11212277
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acridone derivatives: design, synthesis, and inhibition of breast cancer resistance protein ABCG2.
    Boumendjel A; Macalou S; Ahmed-Belkacem A; Blanc M; Di Pietro A
    Bioorg Med Chem; 2007 Apr; 15(8):2892-7. PubMed ID: 17317193
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemosensitivity determinants of irinotecan hydrochloride in hepatocellular carcinoma cell lines.
    Takahata T; Ookawa K; Suto K; Tanaka M; Yano H; Nakashima O; Kojiro M; Tamura Y; Tateishi T; Sakata Y; Fukuda S
    Basic Clin Pharmacol Toxicol; 2008 Apr; 102(4):399-407. PubMed ID: 18248513
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Photodynamic Therapy Synergizes with Irinotecan to Overcome Compensatory Mechanisms and Improve Treatment Outcomes in Pancreatic Cancer.
    Huang HC; Mallidi S; Liu J; Chiang CT; Mai Z; Goldschmidt R; Ebrahim-Zadeh N; Rizvi I; Hasan T
    Cancer Res; 2016 Mar; 76(5):1066-77. PubMed ID: 26719532
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of efflux transporter ABCG2/BCRP does not restore mitoxantrone sensitivity in irinotecan-selected human leukemia CPT-K5 cells: evidence for multifactorial multidrug resistance.
    Su Y; Lee SH; Sinko PJ
    Eur J Pharm Sci; 2006 Oct; 29(2):102-10. PubMed ID: 16844360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A global drug inhibition pattern for the human ATP-binding cassette transporter breast cancer resistance protein (ABCG2).
    Matsson P; Englund G; Ahlin G; Bergström CA; Norinder U; Artursson P
    J Pharmacol Exp Ther; 2007 Oct; 323(1):19-30. PubMed ID: 17616561
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line.
    Perego P; De Cesare M; De Isabella P; Carenini N; Beggiolin G; Pezzoni G; Palumbo M; Tartaglia L; Pratesi G; Pisano C; Carminati P; Scheffer GL; Zunino F
    Cancer Res; 2001 Aug; 61(16):6034-7. PubMed ID: 11507048
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular modeling of new camptothecin analogues to circumvent ABCG2-mediated drug resistance in cancer.
    Nakagawa H; Saito H; Ikegami Y; Aida-Hyugaji S; Sawada S; Ishikawa T
    Cancer Lett; 2006 Mar; 234(1):81-9. PubMed ID: 16309825
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ABCG2 mediates differential resistance to SN-38 (7-ethyl-10-hydroxycamptothecin) and homocamptothecins.
    Bates SE; Medina-Pérez WY; Kohlhagen G; Antony S; Nadjem T; Robey RW; Pommier Y
    J Pharmacol Exp Ther; 2004 Aug; 310(2):836-42. PubMed ID: 15075385
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.
    Lopez JP; Wang-Rodriguez J; Chang C; Chen JS; Pardo FS; Aguilera J; Ongkeko WM
    Arch Otolaryngol Head Neck Surg; 2007 Oct; 133(10):1022-7. PubMed ID: 17938326
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression and functional analyses of breast cancer resistance protein in lung cancer.
    Kawabata S; Oka M; Soda H; Shiozawa K; Nakatomi K; Tsurutani J; Nakamura Y; Doi S; Kitazaki T; Sugahara K; Yamada Y; Kamihira S; Kohno S
    Clin Cancer Res; 2003 Aug; 9(8):3052-7. PubMed ID: 12912956
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.
    Robey RW; Medina-Pérez WY; Nishiyama K; Lahusen T; Miyake K; Litman T; Senderowicz AM; Ross DD; Bates SE
    Clin Cancer Res; 2001 Jan; 7(1):145-52. PubMed ID: 11205902
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.